ASCO 2018 – Sunday, June 3

Sunday, June 3

8-11:30 a.m.
Hall A
POSTER SESSIONS:
Long-term results of a phase 1/2 trial of nelfinavir
with concurrent chemoradiotherapy for locally
advanced non-small cell lung cancer
Poster #158; Abstract 8552
James Stevenson, MD – Author

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Precision medicine for pancreatic cancer patients:
preliminary results from the Know Your Tumor program
Poster #315; Abstract 4126
Davendra Sohal, MD, MPH – Author

SWOG S1505: A randomized phase 2 study of
perioperative mFOLFIRINOX vs. gemcitabine/
nab-paclitaxel as therapy for resectable pancreatic
adenocarcinoma
Poster #331a; Abstract TPS4153
Davendra Sohal, MD, MPH – First author

24-month overall survival from KEYNOTE-021 cohort
G: pemetrexed-carboplatin plus pembrolizumab as
first-line therapy for advanced nonsquamous NSCLC
Poster #349; Abstract 9026
James Stevenson, MD – Author

Economic impact of next-generation sequencing vs.
sequential single-gene testing modalities to detect
genomic alterations in metastatic non-small cell lung
cancer using a decision analytic model
Poster #354; Abstract 9031
Nathan Pennell, MD, PhD – First author

Detection and clearance of RET variants in plasma
cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Poster #371; Abstract 9048
Vamsidhar Velcheti, MD – Author

8:24-8:36 a.m.
Arie Crown Theater
ORAL ABSTRACT SESSION:
Patient-reported outcomes (PROs) in IMmotion151:
atezolizumab (atezo) + bevacizumab (bev) vs.
sunitinib (sun) in treatment-naive metastatic renal cell carcinoma (mRCC)
Abstract 4511
Brian Rini, MD – Author